- Datum09.06.2025
- Uhrzeit19:00 - 20:00 Uhr
- Veranstalter
BNP Paribas
Black Diamond Therapeutics Aktie
Verkaufen
Kaufen
Black Diamond Therapeutics Chart
Black Diamond Therapeutics Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
4,03 %
Intraday
17,27 %
1 Woche
66,45 %
1 Monat
20,56 %
Seit Jahresbeginn
-50,29 %
1 Jahr
32,99 %
3 Jahre
-92,74 %
5 Jahre
Passender Service zu Black Diamond Therapeutics
Webinar zu Black Diamond Therapeutics
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,195-6,750
- Jahrestief / Hoch ($)1,195-2,820
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Black Diamond Therapeutics
Keine Dividenden verfügbar
Termine von Black Diamond Therapeutics
Keine aktuellen Termine
Beschreibung
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
